C A Castaneda1,2, C Torres-Cabala3, M Castillo4, V Villegas4, S Casavilca5, L Cano4, J Sanchez4, J Dunstan6, G Calderon6, M De La Cruz6, J M Cotrina6, H L Gomez7, R Galvez4, J Abugattas6. 1. Medical Oncology Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Surquillo, 15038, Lima, Peru. carloscastanedaaltamirano@yahoo.com. 2. Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Surquillo, 15038, Lima, Peru. carloscastanedaaltamirano@yahoo.com. 3. Departments of Pathology and Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 4. Research Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Surquillo, 15038, Lima, Peru. 5. Pathology Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Surquillo, 15038, Lima, Peru. 6. Breast Cancer Surgery Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Surquillo, 15038, Lima, Peru. 7. Medical Oncology Department, Instituto Nacional de Enfermedades Neoplasicas, Av. Angamos Este 2520, Surquillo, 15038, Lima, Peru.
Abstract
PURPOSE: Acral lentiginous melanoma (ALM) is a poor prognosis subtype and is the most prevalent in non-Caucasian populations. The presence of tumor infiltrating lymphocytes (TILs) has been associated with poor prognosis in melanoma. A large cohort of ALM cases was studied to determine status of TIL and its association with outcome. METHODS: All patients with cutaneous melanoma presenting from 2005 to 2012 at Instituto Nacional de Enfermedades Neoplasicas in Peru were retrospectively identified. Clinicopathological information was obtained from the medical charts. A prospective evaluation of TIL was performed. Analysis of association between ALM and clinicopathological features including TIL as well as survival analysis compared the outcome of ALM to whole group and extremity NALM was performed. RESULTS: 537 ALM from a total of 824 cutaneous melanoma cases were studied. Older age (p = 0.022), higher Breslow (p = 0.008) and ulceration (p < 0.001) were found to be more frequent in ALM. Acral had worse overall survival (OS) compared with the whole group (p = 0.04). Clinical stage (CS) I-II patients had a median OS of 5.3 (95% CI 4.3-6.2) for ALM and 9.2 (95% CI 5.0-7.0) for extremity NALM (p = 0.016). Grade 0 (absence of TIL), I, II and III were found in 7.5, 34.5, 32.1, and 25.9%, respectively. Lower TIL grade was associated with larger tumor size (p = 0.003), higher Breslow (p = 0.001), higher Clark level (p = 0.007), higher CS (p = 0.002), extremity location (p = 0.048), histological subtype ALM (p = 0.024) and better OS (p = 0.001). CONCLUSIONS: ALM is highly prevalent in Peru and carries poor outcome. Lower TIL levels were associated with poor outcome and ALM.
PURPOSE:Acral lentiginous melanoma (ALM) is a poor prognosis subtype and is the most prevalent in non-Caucasian populations. The presence of tumor infiltrating lymphocytes (TILs) has been associated with poor prognosis in melanoma. A large cohort of ALM cases was studied to determine status of TIL and its association with outcome. METHODS: All patients with cutaneous melanoma presenting from 2005 to 2012 at Instituto Nacional de Enfermedades Neoplasicas in Peru were retrospectively identified. Clinicopathological information was obtained from the medical charts. A prospective evaluation of TIL was performed. Analysis of association between ALM and clinicopathological features including TIL as well as survival analysis compared the outcome of ALM to whole group and extremity NALM was performed. RESULTS: 537 ALM from a total of 824 cutaneous melanoma cases were studied. Older age (p = 0.022), higher Breslow (p = 0.008) and ulceration (p < 0.001) were found to be more frequent in ALM. Acral had worse overall survival (OS) compared with the whole group (p = 0.04). Clinical stage (CS) I-II patients had a median OS of 5.3 (95% CI 4.3-6.2) for ALM and 9.2 (95% CI 5.0-7.0) for extremity NALM (p = 0.016). Grade 0 (absence of TIL), I, II and III were found in 7.5, 34.5, 32.1, and 25.9%, respectively. Lower TIL grade was associated with larger tumor size (p = 0.003), higher Breslow (p = 0.001), higher Clark level (p = 0.007), higher CS (p = 0.002), extremity location (p = 0.048), histological subtype ALM (p = 0.024) and better OS (p = 0.001). CONCLUSIONS: ALM is highly prevalent in Peru and carries poor outcome. Lower TIL levels were associated with poor outcome and ALM.
Authors: Lori A Pollack; Jun Li; Zahava Berkowitz; Hannah K Weir; Xiao-Cheng Wu; Umed A Ajani; Donatus U Ekwueme; Chunyu Li; Brian P Pollack Journal: J Am Acad Dermatol Date: 2011-11 Impact factor: 11.527
Authors: Phyllis A Gimotty; Patricia Van Belle; David E Elder; Todd Murry; Kathleen T Montone; Xiaowei Xu; Susan Hotz; Shane Raines; Michael E Ming; Peter Wahl; Dupont Guerry Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: G Paolino; M W Bekkenk; D Didona; L Eibenschutz; A G Richetta; C Cantisani; G Viti; A Carbone; P Buccini; P De Simone; A Ferrari; E Scali; S Calvieri; V Silipo; E Cigna; G P Viti; U Bottoni Journal: Eur Rev Med Pharmacol Sci Date: 2016-03 Impact factor: 3.507
Authors: Danielle M Bello; Joanne F Chou; Katherine S Panageas; Mary S Brady; Daniel G Coit; Richard D Carvajal; Charlotte E Ariyan Journal: Ann Surg Oncol Date: 2013-07-10 Impact factor: 5.344
Authors: Alison L Burton; Brent A Roach; Michael P Mays; Andrea F Chen; Brooke A R Ginter; Abbey M Vierling; Charles R Scoggins; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters Journal: Am Surg Date: 2011-02 Impact factor: 0.688
Authors: W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: C A Castaneda; M Castillo; C Torres-Cabala; L A Bernabe; S Casavilca; V Villegas; J Sanchez; M de la Cruz; J Dunstan; J M Cotrina; H L Gomez; C Chavez; M P Landa-Baella; K Tello; B F Felix; J Abugattas Journal: Clin Transl Oncol Date: 2019-02-16 Impact factor: 3.405
Authors: Yian Ann Chen; Jamie K Teer; Zeynep Eroglu; Jheng-Yu Wu; John M Koomen; Florian A Karreth; Jane L Messina; Keiran S M Smalley Journal: Semin Cancer Biol Date: 2019-11-02 Impact factor: 15.707
Authors: M Mandalà; P Rutkowski; F Galli; R Patuzzo; V De Giorgi; E Rulli; A Gianatti; B Valeri; B Merelli; A Szumera-Ciećkiewicz; D Massi; A Maurichi; P Teterycz; M Santinami Journal: ESMO Open Date: 2022-04-11
Authors: Carolin Kathner-Schaffert; Lina Karapetow; Madlen Günther; Max Rudolph; Mahmoud Dahab; Eileen Baum; Thomas Lehmann; Otto W Witte; Christoph Redecker; Christian W Schmeer; Silke Keiner Journal: Cells Date: 2019-12-17 Impact factor: 6.600
Authors: Shelly X Bian; Lindsay Hwang; Jennifer Hwang; Omar Ragab; Gino K In; David Peng; Eugene Lin Journal: Pigment Cell Melanoma Res Date: 2021-08-02 Impact factor: 4.693